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ISSN: 1556-0864/13/0807-0e66In their report,1 Conklin et al. com-pared five antianaplastic lymphoma 
FIGURE 1.  ALK iAEP IHC in lung cancers with or without ALK fusion genes. Expression of ALK fusion protein is dependent on the 
promoter-enhancer activity of ALK partner genes, including EML4, which are usually housekeeping genes. In ALK fusion-positive 
tumors, therefore, all tumor cells are immunostained for the ALK kinase domain in IHC using anti-ALK antibody directed to the 
kinase domain, when stained appropriately by using a highly sensitive method, such as iAEP. All the cancer cells in an EML4–ALK-
positive lung cancer express EML4-ALK protein (A). Some lung cancer cases (<1%) may express full length ALK. In such a case, the 
staining intensity usually varies from cell to cell, showing staining heterogeneity. This heterogeneity is probably because ALK expres-
sion in these cases is physiological, as in normal nerve cells, and because the ALK promoter-enhancer activity varies among cells. 
ALK rearrangement-negative small-cell carcinoma (B), large-cell neuroendocrine carcinoma (C), and poorly differentiated carcinoma 
(squamous cell carcinoma in this case, D) of lung may sometimes express the full length ALK, and the staining pattern is usually 
heterogeneous. IHC, immunohistochemistry; ALK, anaplastic lymphoma kinase; iAEP, intercalated antibody-enhanced polymer.
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kinase immunohistochemistry (ALK 
IHC) systems. I agree with their conclu-
sion that IHC is reliable for detection of 
ALK rearrangement; however, I would 
like to comment on their interpretation 
of individual results.
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They determined the sensitivity 
and specificity of five systems includ-
ing “any ALK expression by IHC on 
tissue microarray (TMA) or whole 
section (WS),” using fluorescent in 
situ hybridization (FISH) on WS as 
the standard.1 According to their crite-
ria, both sensitivity and specificity of 
ALK1-ADVANCE should be 100%; 
however, these values are stated as 66% 
and 87.5%, respectively, in Table 3.1
A TMA specimen corresponds 
to a part of the WS. Therefore, if a 
TMA scores 2+, the corresponding 
WS should score 2+ focal (hetero-
geneity) or higher. If a WS scores 
2+ diffuse, the corresponding TMA 
always scores 2+. Interestingly, for the 
5A4-Histofine staining in cases 10 and 
11, the TMA and WS results are dif-
ferent by two scores (2+ or 0) (Tables 
1 and 2).1 This score difference might 
be because of either serious staining 
errors, or accidental interchanging of 
the results because such high differ-
ence is unlikely unless heterogeneity 
exists in the WS, and actually, het-
erogeneity was not observed in the 
WS. Similarly, the score difference of 
ALK1-ADVANCE for case 3 is also 
unlikely. Therefore, I would like the 
authors to check these results and re-
stain the sections.
For ALK1 staining, the TMA 
and WS scores show discordance (1+ 
or 0) for cases 3 and 11. Such discor-
dance may occur because the observer 
struggled to determine whether the 
faint positivity of score 1+ was real 
positivity, unlike the readily detect-
able staining of score 2+ and 3+, as 
mentioned by the authors.1 Given that, 
would it be appropriate to define score 
1+ as positive while calculating sensi-
tivity? From this point of view, in case 
11, the best and practical sensitivity 
was obtained only with 5A4-Histofine 
staining—a readily detectable staining 
of score 2+—whereas with other stains, 
the scores were either 1+ or 0 (Table 2).1
In my published2,3 and unpub-
lished records for anti-ALK IHC of more 
than 4500 lung cancer cases by using the 
intercalated antibody-enhanced poly-
mer (iAEP) method,3 a highly-sensitive 
method on which the 5A4-Histofine 
staining is based, almost all cancer cells 
were stained in more than 300 ALK-
rearranged cases. This staining homo-
geneity supports the view that all tumor 
cells of ALK-rearranged tumors harbor 
ALK rearrangement.4 Wild-type ALK 
is weakly expressed physiologically in 
normal nerve cells.5 Therefore, lung 
cancers without ALK rearrangement 
sometimes show positivity in highly 
sensitive anti-ALK IHC, such as the 
iAEP method, especially in cases with 
neuroendocrine differentiation (small-
cell, large-cell neuroendocrine, and 
other carcinomas with focally neuro-
endocrine differentiation).2 However, 
unlike in ALK-rearranged cases, the 
staining pattern in these cases is usu-
ally heterogeneous probably because 
the physiological expression status var-
ies from cell to cell (Fig. 1). In highly 
sensitive anti-ALK IHC for detection 
of ALK rearrangement, therefore, a het-
erogeneous staining pattern should not 
be interpreted as positive for ALK rear-
rangement, but should be considered 
probably negative for ALK rearrange-
ment, and then be confirmed through 
FISH. This anti-ALK IHC interpreta-
tion would have made the specificities 
of 5A4-ADVANCE and 5A4-Histofine 
100% (Table 2).1
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